PT  - JOURNAL ARTICLE
AU  - Thoms, Julie A.I.
AU  - Yan, Feng
AU  - Hampton, Henry R.
AU  - Davidson, Sarah
AU  - Joshi, Swapna
AU  - Saw, Jesslyn
AU  - Sarowar, Chowdhury H.
AU  - Lim, Xin Ying
AU  - Nunez, Andrea C.
AU  - Kakadia, Purvi M.
AU  - Bhuyan, Golam Sarower
AU  - Zou, Xiaoheng
AU  - Nguyen, Mary
AU  - Ghodousi, Elaheh S.
AU  - Koch, Forrest C.
AU  - Vafaee, Fatemeh
AU  - Pickford, Russell
AU  - Raftery, Mark J.
AU  - Hough, Sally
AU  - Buckland, Griselda
AU  - Bailey, Michelle
AU  - Ghodke, Yuvaraj
AU  - Absar, Noorul
AU  - Vaughan, Lachlin
AU  - Pasalic, Leonardo
AU  - Fong, Chun Y.
AU  - Kenealy, Melita
AU  - Hiwase, Devendra K.
AU  - Stoddart, Rohanna I.
AU  - Mohammed, Soma
AU  - Lee, Linda
AU  - Passam, Freda H.
AU  - Larsen, Stephen R.
AU  - Spring, Kevin J.
AU  - Skarratt, Kristen K.
AU  - Rebeiro, Patricia
AU  - Presgrave, Peter
AU  - Stevenson, William S.
AU  - Ling, Silvia
AU  - Tiley, Campbell
AU  - Fuller, Stephen J.
AU  - Roncolato, Fernando
AU  - Enjeti, Anoop K.
AU  - Hoenemann, Dirk
AU  - Lemech, Charlotte
AU  - Jolly, Christopher J.
AU  - Bohlander, Stefan K.
AU  - Curtis, David J.
AU  - Wong, Jason W H
AU  - Unnikrishnan, Ashwin
AU  - Hertzberg, Mark
AU  - Olivier, Jake
AU  - Polizzotto, Mark N.
AU  - Pimanda, John E.
TI  - Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells <em>in vivo</em>
AID  - 10.1101/2024.07.19.24310679
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.19.24310679
4099  - http://medrxiv.org/content/early/2024/07/23/2024.07.19.24310679.short
4100  - http://medrxiv.org/content/early/2024/07/23/2024.07.19.24310679.full
AB  - Hypomethylating agents are used as frontline therapy for myelodysplastic neoplasms (MDS), but clinical response is unpredictable. To determine whether response was associated with in vivo dynamics of DNA hypomethylation, we conducted a phase 2 trial for MDS using both injection and oral azacitidine (AZA). We established that global DNA methylation levels in peripheral blood and bone marrow mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, there were distinct baseline and early drug induced differences in CpG methylation in haematopoietic stem and progenitor cells (HSPCs) in responders compared to non-responders that overlapped with regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. Following six cycles of therapy when clinical response typically manifests, differential hypomethylation in responder HSPCs pointed to marrow adaptation as a driver of enhanced haematopoiesis. Taken together, CpG methylation differences in HSPCs may explain variable response to AZA.Competing Interest StatementF.V. is affiliated with OmniOmics.AI Pty Ltd. C.F. is an advisory board member at Amgen, AbbVie, Adaptive Biotech, BeiGene, Pfizer, Otsuka, and Jazz, a consultant at Novotech, and received speaker fees from Amgen, Pfizer, Servier, BMS, and Astella. D.H. has consultancy agreements with GlaxoSmithKline and Pharming Corp. M.H. is a consultant/advisory board member at Roche, Gilead, Otsuka, Janssen, Beigene, and Takeda. M.N.P. received research funding and/or provision of drug for clinical trials (to institution) from AstraZeneca, BRII Biosciences, Celgene/BMS, CSL Behring, Eli Lilly, Emergent Biosciences, Gilead Pharmaceuticals, GlaxoSmithKline, Grifols, Janssen/Johnson and Johnson, Takeda, ViiV Pharmaceuticals and has advisory roles with Celgene/BMS, Gilead Pharmaceuticals, and ViiV Pharmaceuticals. J.E.P. received research funding and/or provision of drug for clinical trials (to institution) from Celgene/BMS, Astex, Verastem Oncology and received honoraria from Abbvie as an advisory board member. The remaining authors declare no competing financial interests.Clinical TrialNCT03493646Funding StatementThe investigator initiated clinical trial was funded in part by Celgene/BMS (RG172029) with research support from the National Health and Medical Research Council (RG170246, RG211412), Anthony Rothe Memorial Trust (RG182042, RG202657, RG213236), Leukaemia Foundation (RG231257).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol received ethical approval from the South Eastern Sydney Local Health District Human Research Ethics Committee, and participating sites received Institution approval to conduct the trial prior to commencing recruitment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors